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Abstract
To our knowledge, this study is the ﬁrst report on adverse drug reactions and safety proﬁle of TAS-102 for
metastatic colorectal cancer in clinical practice. Serious neutropenia and febrile neutropenia (FN) tended to
occur from days 15 to 21 in the ﬁrst cycle. Careful monitoring of patients with serious neutropenia around day
15 in the ﬁrst cycle should be done to prevent FN.
Background: Unexpected toxicities of newly approved drugs might be revealed in clinical practice after market
launch. This postmarketing surveillance study investigated expected and unexpected adverse drug reactions (ADRs)
of TAS-102 in clinical practice in the ﬁrst 6 months after market launch. Patients and Methods: All metastatic
colorectal cancer (mCRC) patients (pts) received TAS-102 35 mg/m2 as a starting dose orally twice daily for 5
consecutive days, with 2 days of rest per week for 2 weeks, followed by a 14-day rest period. ADRs during treatment
courses were reported spontaneously by attending physicians. Results: From May 26 to November 25, 2014, 3420
mCRC pts were treated with TAS-102 at 1134 institutes in Japan. In total, 370 ADRs (185 ADRs of myelosuppression
and related infection in 125 pts, of which 58 ADRs in 31 pts were serious ADRs [SADRs] and 127 ADRs in 98 pts were
non-SADRs) were observed in 219 pts and included 89 SADRs in 51 pts and 281 non-SADRs in 183 pts (a pt was
counted twice if SADR and non-SADR were experienced). The most frequent ADRs were: myelosuppression
comprising neutropenia (n ¼ 77), leukopenia (n ¼ 28), thrombocytopenia (n ¼ 23), anemia (n ¼ 20), and febrile neu-
tropenia (FN; n ¼ 19). Serious neutropenia and FN tended to occur from days 15 to 21 in the ﬁrst cycle in 12 (75%) of
16 pts. Conclusion: The ADRs and safety proﬁle of TAS-102 in this study was similar to that in recent TAS-102 clinical
trials, without unexpected safety signals. Careful monitoring should be undertaken in pts with serious neutropenia
around day 15 in the ﬁrst cycle of treatment to prevent FN.
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Colorectal cancer is the fourth leading cause of cancer death
worldwide and the third in Japan.1,2 Systemic chemotherapy for
metastatic colorectal cancer (mCRC) has advanced in the past several
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Results of TAS-102 Postmarketing Surveillance Studygrowth factor receptor monoclonal antibody), cetuximab and pan-
itumumab (anti-epidermal growth factor receptor monoclonal anti-
bodies), and regorafenib (oral multikinase inhibitor) are the key
strategy for mCRC treatment.3-5 However, there remains an unmet
medical need in clinical practice for the treatment of mCRC, partic-
ularly in patients who are maintaining good physical conditions but
are refractory or intolerant to all standard therapies.
TAS-102 (Taiho Pharmaceutical Co, Ltd, Tokyo, Japan) is a novel
oral antitumor agent composed of an antineoplastic thymidine-based
nucleoside analogue, triﬂuridine, and the thymidine phosphorylase
inhibitor, tipiracil hydrochloride, at amolar ratio of 1:0.5 (weight ratio,
1:0.471). On the basis of results of a randomized phase II trial,6 TAS-
102 was approved for the ﬁrst time in March 2014 in Japan by the
Pharmaceutical andMedical Devices Agency (PMDA), with an initial
indication being in patients with mCRC only who are refractory to all
standard therapies deﬁned in the Japanese colorectal cancer treatment
guideline,3 and under a conditional approval that required a phase III
trial of TAS-102 (RECOURSE trial), a large-scale global phase III trial
to evaluate the efﬁcacy and safety of TAS-102 versus placebo in pa-
tients with mCRC refractory to all standard chemotherapies. The
RECOURSE trial showed a signiﬁcant improvement in overall sur-
vival and progression-free survival in favor of TAS-102 over placebo,
with a hazard ratio of 0.68 and 0.48, respectively (both P < .0001).7
Accordingly, the indication of TAS-102 was revised to treatment for
patients with mCRC after submission of the positive results of the
RECOURSE trial to the Japanese health authorities in March 2015.
The safety review of TAS-102 in the randomized phase II and
RECOURSE trial revealed myelosuppression and related infection as
identiﬁed risks, and ileus, cardiac disorders, and interstitial lung dis-
ease (ILD) as potential risks. Unexpected serious adverse drug re-
actions (SADRs) not identiﬁed in clinical trials might emerge because
of the rapid increase in the number of patients in real-world clinical
practice as well as its patient diversity from those in clinical trials,
because many patients with mCRC are elderly (median age at diag-
nosis, approximately 70 years).8 In addition, adverse drug reactions
(ADRs) are an important consideration when making treatment de-
cisions. Therefore, it is essential to detect emerging issues of a new
drug as signals, as early as possible in the postmarketing setting, and to
analyze and detect risks to assure the safety of these medical products.
The Pharmaceuticals and Medical Devices Agency in Japan re-
quires marketing authorization holders (MAH) to conduct early
postmarketing phase vigilance as a pharmacovigilance strategy of the
risk management plan for new drugs approved in Japan since 2014.
MAH undertake safety assurance activities within the ﬁrst 6 months
after market launch of the drug to collect information of ADRs from
a wide patient population to promote proper use of a new drug in
clinical practice and to assure early detection of SADRs.9
The aim of this postmarketing surveillance study was to inves-
tigate the expected and unexpected ADRs of TAS-102 in real-world
clinical practice, compared with those reported from previously
observed data of clinical trials, to facilitate the proper use of TAS-
102 in clinical practice.
Patients and Methods
The postmarketing surveillance study of TAS-102 was conducted
to collect accurate information of ADRs in patients with mCRC
treated with TAS-102 from May 26 to November 25, 2014.- Clinical Colorectal Cancer December 2016Eligible patients were mCRC patients refractory to all standard
chemotherapies, who provided informed consent before treatment,
were not receiving combination treatment with other cytotoxic or
biological agents, with no history of serious hypersensitivity re-
actions to any components of TAS-102, and were not pregnant or
lactating. This study was conducted in accordance with Good
Vigilance Practice (GVP) of the Ministry of Health, Labour, and
Welfare, Japan. Approval by the ethics committee of each institu-
tion was not mandatory, because GVP does not require such
approval for a postmarketing surveillance study.
This was a postmarketing surveillance study, in which the ADR
collection is dependent upon spontaneous reporting. The number
of TAS-102 prescriptions and patients treated with TAS-102 during
the study period are only estimates on the basis of a preregistration
system, in which registration forms were faxed to the Patient
Registration Center from the institute before TAS-102 was
administered. Because the preregistration by fax was not mandatory,
the precise number of patients could not be determined. However,
the company strongly recommended, from the proper use stand-
point, that all physicians register patients by fax. The number of
registrations by fax supported the estimated number of patients who
were prescribed TAS-102 in daily practice.
A treatment cycle included 35 mg/m2 of TAS-102 as a starting
dose administered orally twice daily 1 hour after breakfast and
dinner, for 5 consecutive days, with 2 days of rest per week for 2
weeks, followed by a 14-day rest period. To assure proper use of
TAS-102 and patient safety, a “Guidance on the proper usage of
TAS-102” document was distributed to health care professionals.
This included guidance regarding facility requirements, patient
criteria for starting treatment, periodic laboratory tests, prophylaxis
and early detection of adverse reactions, coordination with a
specialist for respective adverse reactions, and informed consent.
Facility requirements included the presence of expert physicians,
and availability of emergency treatments. Cooperation for all-case
preregistration criteria for starting TAS-102 treatment were:
Eastern Cooperative Oncology Group performance status (PS) of
0 or 1, absolute neutrophil count of 1500/mm3, platelet
count 75,000/mm3, hemoglobin 8.0 g/dL, aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) 100 IU/L
(for patients with liver metastases, AST and ALT 200 IU/L), total
bilirubin 1.5 mg/dL, serum creatinine 1.5 mg/dL, no evidence
of active infection, peripheral neuropathy Grade 2, and other
nonhematological toxicities Grade 1 (excluding alopecia, dys-
geusia, pigmentation, and symptoms associated with the primary
cancer), according to Common Terminology Criteria for Adverse
Events version 3.0. These criteria were determined on the basis of
the protocol of the randomized phase II trial for TAS-102.6
Adverse drug reactions were deﬁned as events for which a causal
relationship with TAS-102 could not be ruled out or was unknown.
SADR was deﬁned as any event that resulted in death, was incapa-
citating, required inpatient hospitalization or prolongation of existing
hospitalization for treatment, was equivalent in seriousness to any of
the aforementioned events, or resulted in a congenital anomaly/birth
defect according to International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) E2D10 and E2A11 guidelines. A patient was
counted twice if experiencing SADR(s) and non-SADR(s).
Table 1 Patient Characteristics (n [ 3420a)
Characteristics Value %
Mean Age (Range),
Years
66 (24-92) e
<70 2149 62.84
70 1270 37.13
Unknown 1 0.03
Sex
Male 2065 60.38
Female 1355 39.62
ECOG Performance
Status
0 or 1 3396 99.30
2 21 0.61
3 3 0.09
Combination Agent
Yesb 2 0.06
No 3418 99.94
Mean Body Mass
Index (Range)
21.90 (12.45-42.67) e
Total Bilirubin
1.5 mg/dL 3355 98.10
>1.5 mg/dL 64 1.87
Unknown 1 0.03
Creatinine
1.5 mg/dL 3408 99.65
>1.5 mg/dL 12 0.35
Neutrophil Count
<1500/mm3 11 0.32
1500/mm3 3409 99.68
Platelet Count
<75,000/mm3 19 0.56
75,000/mm3 3400 99.42
Unknown 1 0.03
Hemoglobin
<8.0 g/dL 27 0.79
8.0 g/dL 3392 99.18
Unknown 1 0.03
AST
<100 IU/L 3392 99.18
100 IU/L 28 0.82
ALT
<100 IU/L 3404 99.53
100 IU/L 16 0.47
Infection
Yes 1 0.03
No 3419 99.97
Table 1 Continued
Characteristics Value %
Peripheral Sensory
Neuropathy
Grade 2 3410 99.71
Grade 3 7 0.20
Unknown 3 0.09
Diarrhea
Yes 2 0.06
No 3417 99.91
Unknown 1 0.03
Other
(Nonhematological)
Yesc 5 0.15
No 3415 99.85
Data are presented as n (%) except where otherwise noted.
Abbreviations: ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; ECOG ¼
Eastern Cooperative Oncology Group.
aEstimated number of patients, on the basis of the number of registration forms faxed to the
Patient Registration Center from the institute.
bBevacizumab (n ¼ 2).
cAnorexia (n ¼ 1), dyspnea (n ¼ 1), proteinuria (n ¼ 2), rash (n ¼ 1).
Takayuki Yoshino et alTo ensure appropriate use of TAS-102 and early detection of
ADRs, all patients were required to undergo examinations of their
physical and nonphysical conditions on the day before starting
treatment, and on days 15 and 22 of the ﬁrst treatment cycle.
Thereafter, patients were to undergo examination on the day beforestarting treatment and on day 15 of each treatment cycle (see
Supplemental Tables 1 and 2 in the online version).
Role of the Funding Source
The sponsor contributed to study design, data collection, and
data interpretation. The corresponding author had full access to all
of the data in the study and has the responsibility of the ﬁnal de-
cision to submit for publication.
Results
The number and characteristics of patients were obtained from the
data provided in the preregistration fax during enrollment. During
the 6-month period, 3420 patients (male, 2065 patients; 60.4%)
from 1134 institutes were registered. Median age of the patients was
66 (range, 24-92) years; 2149 patients were younger than 70 years,
and 1270 patients were 70 years or older (1 patient, age unknown).
Median body mass index was 21.9 (range, 12.5-42.7) kg/m2. Most
patients had PS 0 or 1 (99.3%; 3396 patients), followed by PS 2
(0.6%; 21 patients), and PS 3 (0.1%; 3 patients) (Table 1).
On the basis of spontaneous reports by attending physicians, a total
of 370 ADRswere observed in 219 patients and included 89 SADRs in
51 patients and 281 non-SADRs in 183 patients. A signiﬁcant increase
in either SADR or non-SADR in patients 70 years or older was not
apparent compared with patients younger than 70 years.
Hematological ADRs
Of 370 ADRs, a total of 185 ADRs of myelosuppression and
related infections were observed in 125 patients, of which 58 ADRs
in 31 patients were SADRs and 127 ADRs in 98 patients were non-
SADRs.
The major ADRs of myelosuppression were neutropenia,
leukopenia, thrombocytopenia, anemia, and febrile neutropenia
(FN). In total, there were 167 ADRs among these major
hematological ADRs, comprised of neutropenia (7 SADRs and 70Clinical Colorectal Cancer December 2016 - e207
Table 2 Adverse Drug Reactions Proﬁle for TAS-102 in Real-
World Clinical Practice
ADR Non-SADR SADR Total
Hematological
Neutropenia 70 7 77
Leukopenia 25 3 28
Thrombocytopenia 14 9 23
Anemia 12 8 20
FN 1 18 19
Infections 0 6 6
Others 5 7 12
Nonhematological
Nausea 31 2 33
Anorexia 27 4 31
Diarrhea 20 5 25
Fatigue 17 0 17
Vomiting 11 2 13
ILD 0 7 7
Others 48 11 59
Data are presented as n.
Abbreviations: ADR ¼ adverse drug reaction; FN ¼ febrile neutropenia; ILD ¼ interstitial lung
disease; SADR ¼ serious adverse drug reaction.
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e208non-SADRs), leukopenia (3 SADRs and 25 non-SADRs), throm-
bocytopenia (9 SADRs and 14 non-SADRs), anemia (8 SADRs and
12 non-SADRs), and FN (18 SADRs and 1 non-SADR) (Table 2).
Further, 162 of the 167 ADRs (97%) were conﬁrmed to have
resolved or were resolving.
Serious neutropenia and FN tended to occur from days 15 to 21 in
the ﬁrst treatment cycle in 12 (75.0%) of 16 patients (Figure 1).
Fourteen of the 16 patients were conﬁrmed to have recovered or were
recovering; among them, 64.2% (9 patients) recovered or were
recovering around day 6 after onset (median, 7 days; range, 5-20
days). A detailed investigation report was available in 11 patients, and
showed that granulocyte-colony stimulating factor (G-CSF) was given
to 8 patients (72.7%) and prophylactic and/or therapeutic antibiotics
to 10 patients (90.9%). Treatment-related death due to infection
induced by serious neutropenia was observed in 2 patients—1
experienced FN on day 15 and the other experienced it on day 18.Figure 1 Onset of Serious Neutropenia and Febrile
Neutropenia (FN) in the First Treatment Cycle
- Clinical Colorectal Cancer December 2016In 36 of the 52 patients, nonserious neutropenia tended to occur
from days 22 to 28 in the ﬁrst treatment cycle (Figure 2); it was
conﬁrmed that all patients had recovered or were recovering with
appropriate therapeutic measures. In 23 of the 52 patients (44.2%),
neutropenia had resolved or was resolving at around day 7 after
onset (median, 10 days; range, 2-89 days).
Nonhematological ADRs
Interstitial lung disease was observed in 7 patients, including 3
patients with a history of ILD related to previous treatment, and all
patients were conﬁrmed to have recovered or were recovering
(Table 3). Median time to onset was 51 days (range, 22-91 days),
and median time to recovery was 10 days (range, 7-39 days).
Twenty-ﬁve ADRs of diarrhea were observed in 25 patients, of
which 5 were serious. Of the 5 patients, 4 were conﬁrmed to have
recovered, and 1 did not recover and died due to infection sec-
ondary to myelosuppression.
Forty-six ADRs, comprising 33 ADRs of nausea and 13 of
vomiting, were observed in 38 patients; of these, 2 ADRs each of
nausea and vomiting in 3 patients were serious. The median onset
of nausea was day 6 for these 33 ADRs. All 3 patients with serious
nausea/vomiting were conﬁrmed to have recovered between days 6
and 8 after onset. Thirty-one ADRs of decreased appetite were
observed in 31 patients of whom 4 were SADRs. Decreased appetite
was most frequently observed to have developed on day 8 of
treatment. Seventeen ADRs of fatigue/malaise were observed in 17
patients, but were nonserious. Three ADRs of cardiac disorders were
observed in 2 patients; of these, 1 patient with concurrent cardiac
ischemia developed decreased left ventricular function and the
other, with a history of myocardial infarction and complications of
hypertension, hyperlipidemia, and diabetes mellitus, experienced
congestive heart failure and atrial ﬁbrillation after receiving TAS-
102. Ileus was not observed in any patients.
Discussion
To our knowledge, this postmarketing surveillance study is the
ﬁrst on ADRs and safety proﬁle of TAS-102 for mCRC patients in
the ﬁrst 6 months after market launch from its use in real-world
clinical practice worldwide since TAS-102 was ﬁrst approved in
Japan. There are limitations to this study because information
regarding ADRs and SADRs was obtained through spontaneousFigure 2 Onset of Nonserious Neutropenia in the First
Treatment Cycle
Table 3 Characteristics of Each Patient With ILD
Age Sex PS Time to Onset
Time to
Outcome (Days) Outcome
Concurrent
Conditions History of ILD
History of
Drug Allergy
Smoking
History
50s Female 0 Day 22 7 Recovered Hypertension,
genital
hemorrhage
e e None
70s Male 0 Day 32 26 Recovered e FOLFOX with
panitumumab
e 7 Cigarettes per
day for 15 years
60s Male 2 Day 34 9 Recovered Pneumonia Regorafenib e None
60s Male 1 Day 52 17 Recovering Diabetes mellitus e e 20 Cigarettes per
day for 45 years
50s Male 0 Day 54 10 Recovered e e Panitumumab None
70s Male 1 Day 51 39 Recovered with
sequelaea
e 5-FU/LV e None
70s Male 2 Day 91 7 Recovering e e e 20 Cigarettes per
day for 46 years
Abbreviations: FOLFOX ¼ ﬂuorouracil and leucovorin plus oxaliplatin; 5-FU ¼ ﬂuorouracil; ILD ¼ interstitial lung disease; LV ¼ leucovorin; PS ¼ performance status.
aSequelae: prolonged consciousness disturbance.
Takayuki Yoshino et alreporting. Because of this, the actual number of patients enrolled in
this study as well as the ADR and SADR frequencies could not be
calculated. The patient characteristics obtained via fax were referred
to analyze the patient characteristics in this study.
In this study, serious neutropenia and FN tended to occur from
days 15 to 21 in the ﬁrst treatment cycle in 12 (75.0%) of the 16
patients, and resolved promptly or was resolving with the use of
G-CSF or with prophylactic and/or therapeutic antibiotics. A drug
rest period of 2 weeks, in accordance with a 5 days-on and 2 days-
off schedule for 2 weeks, was set as the convalescence period from
hematological toxicity on the basis of results from previous phase I
studies.12-16 Because the nadir of hematological toxicity was most
frequently observed during the 2-week rest period in this study, the
setting of this rest period was supported by our results as well as
those from previous clinical trials.
Serious neutropenia might result in a fatal outcome, because
there were 2 patients who died because of infection resulting from
serious neutropenia. The prophylactic use of G-CSF is not allowed
in Japan. Therefore, G-CSF was not used prophylactically in the
randomized phase II trial or the RECOURSE trial, although the
proactive use of G-CSF as supportive care when observing neu-
tropenia was allowed. The proportion patients who experienced
neutropenia who received G-CSF as supportive care was reported to
be 9% in the RECOURSE trial,7 and was reported as 21.8% by
Kotani et al.17 Thus, ﬁndings from this study suggest that appro-
priate measures such as dose adjustment, drug discontinuation, and/
or use of G-CSF and prophylactic and/or therapeutic antibiotics
need to be considered in patients with neutropenia.
Interstitial lung disease was observed in 7 patients, all of whom
were conﬁrmed to have recovered or were recovering; of these, 3
patients had a history of ILD associated with previous chemo-
therapy. In a phase II study conducted in Japan, ILD was noted in 1
of 113 patients (0.9%). This case of ILD was considered to be
associated with a viral infection on the basis of the clinical course
and lung biopsy, and causality associated with TAS-102 was ruled
out. No ILD was observed in the RECOURSE trial. However,
these ﬁndings suggest that careful attention is required when TAS-
102 is administered in patients with a history of ILD.Furthermore, this study showed that diarrhea might occur at any
time during the ﬁrst cycle of TAS-102 treatment and tends to
resolve in a relatively short period of time. In case of nausea, most
patients experienced the ADRs within 7 days after starting the
treatment; this tendency was also observed for anorexia.
The inclusion criteria of this study were established on the basis of
the “Guidance on the proper usage of TAS-102 document.” In this
study, 3396 of 3420 patients (99.3%) registered by fax had a PS 0 or 1.
More toxicity might occur if patients with more advanced disease are
involved. In their recent publication on the clinical use of TAS-102, Dr
Kotani and colleagues reported no signiﬁcant difference betweenPS0-1
andPS2 patients in terms of the safety proﬁle, although their report was
solely on the patients observed in their hospital.17
Only Japanese patients were enrolled in this study. However, a
geographic analysis of the RECOURSE trial, which was conducted
globally, suggested no ethnic difference in terms of the safety proﬁle.18
In addition, in the phase I study conducted in the United States by
Dr Bendell and colleagues, no safety proﬁle difference was found
between the Japanese and Caucasian populations.19 Therefore, we
believe that the results from this study can be applied to Caucasian
populations. In addition, an expanded access program currently
ongoing in theUnited States might also support the conclusion of this
study (ie, there is no ethnic difference between Japanese and Cauca-
sian populations with regard to the use of TAS-102).
Achieving a treatment period with TAS-102 for as long as
possible, while minimizing toxicity risks to maintain a positive
beneﬁt:risk balance, is a key strategy for treating mCRC patients.
The results from this study reﬂect ADR proﬁles of TAS-102 in real-
world clinical practice. Although there are limitations to this study,
recognition of the proﬁle of ADRs over time can help health care
professionals to prepare for the effect of these events on real-world
mCRC patients, who are typically elderly and have already been
exposed to a range of toxicities from previous lines of therapy. In
addition, the most common ADRs identiﬁed in the study have been
frequently observed in TAS-102 clinical trials, and awareness of this
consistent toxicity proﬁle allows health care professionals to advise
patients on early identiﬁcation and reporting of symptoms. The
time proﬁle of ADR occurrences in this study highlights theClinical Colorectal Cancer December 2016 - e209
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initiating treatment. A number of measures have been identiﬁed
that help prevent or limit the effects of ADRs.
Another prospective postmarketing surveillance study of TAS-
102 with a large sample size is now ongoing in Japan. This study
is conducted as part of another pharmacovigilance strategy to
examine factors affecting the safety and efﬁcacy of TAS-102 treat-
ment in clinical practice for mCRC patients. This study was
designed to observe the frequency of ADRs and SADRs in patients
with or without impaired renal function or liver dysfunction.
Conclusion
The ADR and safety proﬁle of TAS-102 observed in this post-
marketing surveillance study in clinical practice were similar to those
from recent TAS-102 randomized clinical trials. There were no un-
expected safety signals. Careful monitoring of myelosuppression
should be undertaken, to prevent FN, especially in patients who
develop serious neutropenia around day 15 in theﬁrst treatment cycle.
Clinical Practice Points
 Newly approved drugs might have unexpected toxicities that
emerge in clinical practice after market launch.
 To our knowledge, this large-scale surveillance study is the ﬁrst
to show the safety proﬁle of TAS-102 in real-world clinical
practice among patients with mCRC refractory to all standard
chemotherapies.
 The ADR and safety proﬁle of TAS-102 observed in this sur-
veillance study were similar to those from recent TAS-102 ran-
domized clinical trials. Careful monitoring of patients with
serious neutropenia around day 15 in the ﬁrst treatment cycle
should be undertaken to prevent FN.
 This study was undertaken worldwide to investigate expected
and unexpected ADRs of TAS-102 in real-world clinical practice,
including at nonspecialized hospitals, in the ﬁrst 6 months after
its launch in Japan.
 In addition, awareness of a consistent toxicity proﬁle allows
health care professionals to advise patients regarding early iden-
tiﬁcation and reporting of symptoms.
 The time proﬁle of ADR occurrences in this study highlights the
importance of initiating proactive monitoring of patients when
initiating treatment.Acknowledgments
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Supplemental Table 1 Dosage and Administration of TAS-102
According to BSA
BSA, m2
Dosage, mg (Twice
Daily) Total Daily Dose, mg
<1.07 35 70
1.07-1.22 40 80
1.23-1.37 45 90
1.38-1.52 50 100
1.53-1.68 55 110
1.69-1.83 60 120
1.84-1.98 65 130
1.99-2.14 70 140
2.15-2.29 75 150
‡2.30 80 160
BSA is calculated to 2 decimal places.
Abbreviation: BSA ¼ body surface area.
Supplemental Table 2 Examination Schedule for Patients Administered TAS-102 During the Treatment Cycle
Observation
Cycle 1 Cycle 2 and Subsequent Cycles
Before the
Start of First
Cycle Day 8 Day 15 Day 22
Before the
Start of Next
Cycle Day 8 Day 15 Day 22
Clinical Symptoms b c b b b d b d
Body Weighta b d d d b d d d
Performance Status b d d d b d d d
Vital Signs and
Physical Findings
b c b b b d b d
Bone Marrow
Function
b c b b b d b d
Hepatic Function b c b b b d b d
Renal Function b c b b b d b d
aDosage should be modiﬁed if body weight decreases by more than 10% compared with the previous cycle of treatment.
bMust do.
cIf at all possible.
dIf any abnormal ﬁndings are observed.
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